Evidence map›Paper›PMID 34176494›Full record

ArticleJournal of nanobiotechnology2021

Nanoparticles prepared from pterostilbene reduce blood glucose and improve diabetes complications.

Xi Zhao, Anhua Shi, Qiong Ma, Xueyan Yan, Ligong Bian, Pengyue Zhang, Junzi Wu

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Exosome-like Nanoparticles Extracted from Plant Cells for Diabetes Therapy.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xi Zhao *Yunnan Provincial Key Laboratory of Molecular Biology for Sinomedicine, School of Basic Medical, Yunnan University of Chinese Medicine, Kunming, Yunnan, 650500, P.R. China.
Anhua Shi *Yunnan Provincial Key Laboratory of Molecular Biology for Sinomedicine, School of Basic Medical, Yunnan University of Chinese Medicine, Kunming, Yunnan, 650500, P.R. China.
Qiong MaYunnan Provincial Key Laboratory of Molecular Biology for Sinomedicine, School of Basic Medical, Yunnan University of Chinese Medicine, Kunming, Yunnan, 650500, P.R. China.
Xueyan YanCollege of Clinical Medical, Kunming Medical University, Kunming, Yunnan, 650500, PR China.
Ligong BianCollege of Basic Medicine, Kunming Medical University, Kunming, Yunnan, 650500, PR China.
Pengyue ZhangKey Laboratory of Acupuncture and Tuina for Treatment of Encephalopathy, College of Acupuncture, Tuina and Rehabilitation, Yunnan University of Traditional Chinese Medicine, Kunming, 650500, China. zpy19802000@163.com.
Junzi WuYunnan Provincial Key Laboratory of Molecular Biology for Sinomedicine, School of Basic Medical, Yunnan University of Chinese Medicine, Kunming, Yunnan, 650500, P.R. China. xnfz@ynutcm.edu.cn.ORCID http://orcid.org/0000-0002-2976-5299
Yunnan University · CNKunming Medical University · CNYunnan University of Traditional Chinese Medicine · CN

Funding

Applied Basic Research Key Project of Yunnan (CN) 2019FF002 (-055)Yunnan Province Natural Science Foundation of China 30172110104
6 · The paper itself

Abstract

backgroundDiabetes complications are the leading cause of mortality in diabetic patients. The common complications are decline in antioxidant capacity and the onset of micro-inflammation syndrome. At present, glucose-responsive nanoparticles are widely used, as they can release insulin-loaded ultrafine particles intelligently and effectively reduce blood sugar. However, the toxicology of this method has not been fully elucidated. The plant extracts of pterostilbene (PTE) have a wide range of biological applications, such as antioxidation and inflammatory response improvement. Therefore, we have proposed new ideas for the cross application of plant extracts and biomaterials, especially as part of a hypoglycaemic nano-drug delivery system.

resultsBased on the PTE, we successfully synthesised poly(3-acrylamidophenyl boric acid-b-pterostilbene) (p[AAPBA-b-PTE]) nanoparticles (NPs). The NPs were round in shape and ranged between 150 and 250 nm in size. The NPs possessed good pH and glucose sensitivity. The entrapment efficiency (EE) of insulin-loaded NPs was approximately 56%, and the drug loading (LC) capacity was approximately 13%. The highest release of insulin was 70%, and the highest release of PTE was 85%. Meanwhile, the insulin could undergo self-regulation according to changes in the glucose concentration, thus achieving an effective, sustained release. Both in vivo and in vitro experiments showed that the NPs were safe and nontoxic. Under normal physiological conditions, NPs were completely degraded within 40 days. Fourteen days after mice were injected with p(AAPBA-b-PTE) NPs, there were no obvious abnormalities in the heart, liver, spleen, lung, or kidney. Moreover, NPs effectively reduced blood glucose, improved antioxidant capacity and reversed micro-inflammation in mice.

conclusionsp(AAPBA-b-PTE) NPs were successfully prepared using PTE as raw material and effectively reduced blood glucose, improved antioxidant capacity and reduced the inflammatory response. This novel preparation can enable new combinations of plant extracts and biomaterials to adiministered through NPs or other dosage forms in order to regulate and treat diseases.

Indexed as

AnimalsBiocompatible MaterialsBlood GlucoseBoronic AcidsCell Line, TumorCell SurvivalDiabetes ComplicationsDiabetes Mellitus, ExperimentalDrug CarriersDrug Delivery SystemsFemaleGlucoseHumansHydrogen-Ion ConcentrationHypoglycemic AgentsInsulin3-acrylamidophenylboronic acidBiocompatible MaterialsBlood GlucoseBoronic AcidsDrug CarriersGlucoseHypoglycemic AgentsInsulinpterostilbeneStilbenes3-acrylamidophenylboronic acid (AAPBA)Diabetes complicationsDiabetes mellitusInsulin deliveryNano-carrierPterostilbene (PTE)

Identifiers

PMID34176494
PMCPMC8237509
OpenAlexW3176420036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.